Published in World J Urol on October 29, 2003
Behavioral stress accelerates prostate cancer development in mice. J Clin Invest (2013) 1.52
Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis (2008) 0.95
The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem (2010) 0.94
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. PLoS One (2013) 0.79
5α-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores. PLoS One (2017) 0.76
Bioglycans and natural glycosides as a promising research topic in bioorganic chemistriy. Acta Naturae (2010) 0.75
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol (1997) 4.70
Osteoporosis after orchiectomy for prostate cancer. J Urol (1997) 4.32
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A (1996) 3.56
The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem (1968) 3.54
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol (2000) 2.47
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem (2000) 2.29
Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J Biol Chem (1999) 2.28
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2001) 2.11
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech (2000) 2.00
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res (1995) 1.98
Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem (1999) 1.98
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res (2003) 1.96
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res (1998) 1.92
Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol (2000) 1.83
Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst (1999) 1.81
Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem (1999) 1.76
Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med (1984) 1.75
Androgen receptor mutations in prostate cancer. Cancer Res (2000) 1.74
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol (1995) 1.73
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol (1993) 1.69
Clusterin is a secreted mammalian chaperone. Trends Biochem Sci (2000) 1.63
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res (1997) 1.62
Overexpression of clusterin in human breast carcinoma. Am J Pathol (2000) 1.56
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res (2003) 1.56
The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am (1999) 1.55
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47
Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res (2000) 1.41
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate (1996) 1.36
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res (2000) 1.35
Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A (1998) 1.33
Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol (1999) 1.33
Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res (1995) 1.33
Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer (1997) 1.32
Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol (2002) 1.31
Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate (2002) 1.28
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol (1994) 1.25
Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer (1998) 1.18
A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol (1996) 1.17
Androgen-repressed messages in the rat ventral prostate. Prostate (1986) 1.16
Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol (1997) 1.13
Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem (2000) 1.11
Active cell death in hormone-dependent tissues. Cancer Metastasis Rev (1992) 1.10
Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol (2001) 1.10
The IGF axis in the prostate. Horm Metab Res (1994) 1.08
Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol (1994) 1.08
Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int (1998) 1.04
Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res (2003) 0.97
Estrogens in the treatment of prostate cancer. J Urol (1995) 0.97
Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci U S A (1991) 0.94
Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets (2002) 0.93
Clusterin and the kidney. Exp Nephrol (1995) 0.93
Clusterin: a role in cell survival in the face of apoptosis? Prog Mol Subcell Biol (1996) 0.93
High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology (1996) 0.89
A brief history of testosterone. J Urol (2001) 0.88
Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate (2000) 0.87
SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int (1991) 0.87
Rejuvenation in the early 20th century. Andrologia (1998) 0.86
Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate (1997) 0.86
The testis and tissue transplantation: historical aspects. J Reprod Immunol (1990) 0.85
Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest (1992) 0.85
Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol (1998) 0.84
Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep (2003) 0.84
Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res (1999) 0.82
Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration. Urology (1996) 0.81
Adrenal steroids in human prostatic cancer cell lines. Arch Androl (2001) 0.80
Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 . Prostate (2000) 0.79
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol (1998) 0.77
Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology (2002) 0.76
Tissue engineering from Adam to the zygote: historical reflections. World J Urol (2000) 0.76
Charles-Edouard Brown-Séquard: double-hyphenated neurologist and forgotten father of endocrinology. Diabet Med (1994) 0.75
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res (2004) 1.66
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther (2004) 1.63
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2013) 1.58
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem (2007) 1.55
Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs (2002) 1.54
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncol Nurs Forum (2003) 1.50
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res (2004) 1.44
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate (2004) 1.40
Prostate specific antigen: an updated review. Can J Urol (2003) 1.39
A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int (2007) 1.38
Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate (2002) 1.28
Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 1.28
Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res (2002) 1.20
Loss of PTEN is associated with progression to androgen independence. Prostate (2006) 1.20
Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol (2007) 1.19
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.18
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res (2012) 1.17
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int (2008) 1.17
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res (2010) 1.16
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res (2012) 1.16
Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int (2011) 1.15
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2013) 1.12
Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer. Cancer Nurs (2007) 1.12
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res (2010) 1.12
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol (2013) 1.06
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem (2006) 1.06
Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol (2002) 1.05
Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer (2012) 1.05
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol (2005) 1.05
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.04
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol (2014) 1.04
Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci (2013) 1.04
Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate (2004) 1.04
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev (2013) 1.04
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res (2011) 1.02
Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer (2009) 1.02
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int (2006) 1.02
The importance of integrin-linked kinase in the regulation of bladder cancer invasion. Int J Cancer (2011) 1.02
A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res (2012) 1.01
Novel targets and approaches in advanced prostate cancer. Curr Opin Urol (2007) 1.01
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res (2005) 1.01
A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res (2011) 1.00
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology (2002) 1.00
Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int (2011) 0.99
Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2011) 0.99
Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. BJU Int (2012) 0.99
A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther (2005) 0.98
Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Mol Cancer Ther (2009) 0.98
Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res (2004) 0.98
Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res (2003) 0.97
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer (2014) 0.96
Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol (2005) 0.96
IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer (2013) 0.96
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther (2012) 0.95
Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate (2008) 0.94
GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget (2014) 0.94
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol (2012) 0.92
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res (2006) 0.92
Therapeutic options in advanced prostate cancer: present and future. Curr Urol Rep (2007) 0.91
Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate (2010) 0.91
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol (2013) 0.90
Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol (2006) 0.90
PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol Cell Biol (2008) 0.90